{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:35:30Z","timestamp":1794540930681,"version":"4.9.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Unrestricted Educational Grant, Center for Psychedelics and Health Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Mental Health Res"],"DOI":"10.1038\/s44184-026-00226-1","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:22:52Z","timestamp":1785144172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults"],"prefix":"10.1038","volume":"5","author":[{"given":"J.","family":"Swainson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Polard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Borle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Burback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Khullar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Brietzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. N.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"226_CR1","doi-asserted-by":"publisher","unstructured":"Lam, R. W. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: R\u00e9seau canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes. Can. J. Psychiatry https:\/\/doi.org\/10.1177\/07067437241245384 (2024).","DOI":"10.1177\/07067437241245384"},{"key":"226_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/0706743720970860","volume":"66","author":"J Swainson","year":"2021","unstructured":"Swainson, J. et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du R\u00e9seau Canadien Pour Les Traitements De L\u2019humeur Et De L\u2019anxi\u00e9t\u00e9 (Canmat) Concernant L\u2019utilisation De La K\u00e9tamine Rac\u00e9mique Chez Les Adultes Souffrant De Trouble D\u00e9pressif Majeur. Can. J. Psychiatry 66, 113\u2013125 (2021).","journal-title":"Can. J. Psychiatry"},{"key":"226_CR3","doi-asserted-by":"publisher","unstructured":"McIntyre, R. S. et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am. J. Psychiatry https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081251 (2021).","DOI":"10.1176\/appi.ajp.2020.20081251"},{"key":"226_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham, L. N. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 20, 97\u2013170 (2018).","journal-title":"Bipolar Disord."},{"key":"226_CR5","unstructured":"Janssen, R. et al. Interventional Psychiatry and emerging treatments for Posttraumatic Stress Disorder (PTSD): a systematic review. Psychiatry Clin. Psychopharmacol. 35, S57 (2025)."},{"key":"226_CR6","doi-asserted-by":"publisher","unstructured":"Kwan, A. T. H. et al. Ketamine for the treatment of psychiatric disorders: a systematic review and meta-analysis. CNS Spectr. 1\u20138. https:\/\/doi.org\/10.1017\/S1092852924000580(2024)","DOI":"10.1017\/S1092852924000580"},{"key":"226_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2025.209705","volume":"175","author":"R Janssen-Aguilar","year":"2025","unstructured":"Janssen-Aguilar, R. et al. Role of ketamine in the treatment of substance use disorders: a systematic review. J. Subst. Use Addict. Treat. 175, 209705 (2025).","journal-title":"J. Subst. Use Addict. Treat."},{"key":"226_CR8","doi-asserted-by":"publisher","first-page":"40037","DOI":"10.31083\/AP40037","volume":"26","author":"F L\u00f3pez-Mu\u00f1oz","year":"2025","unstructured":"L\u00f3pez-Mu\u00f1oz, F. et al. Did Serendipity contribute to the discovery of new antidepressant drugs? Historical analysis using operational criteria. Alpha Psychiatry 26, 40037 (2025).","journal-title":"Alpha Psychiatry"},{"key":"226_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/14737175.2019.1640604","volume":"19","author":"J Swainson","year":"2019","unstructured":"Swainson, J. et al. Esketamine for treatment resistant depression. Expert Rev. Neurother. 19, 899\u2013911 (2019).","journal-title":"Expert Rev. Neurother."},{"key":"226_CR10","first-page":"340","volume":"44","author":"R Bahr","year":"2019","unstructured":"Bahr, R., Lopez, A. & Rey, J. A. Intranasal Esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. Pharm. Ther. 44, 340\u2013375 (2019).","journal-title":"Pharm. Ther."},{"key":"226_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/cpt.3478","volume":"117","author":"KA Vekhova","year":"2025","unstructured":"Vekhova, K. A., Namiot, E. D., Jonsson, J. & Schi\u00f6th, H. B. Ketamine and esketamine in clinical trials: FDA-approved and emerging indications, trial trends with putative mechanistic explanations. Clin. Pharm. Ther. 117, 374\u2013386 (2025).","journal-title":"Clin. Pharm. Ther."},{"key":"226_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jpsychires.2021.02.020","volume":"137","author":"B Sanders","year":"2021","unstructured":"Sanders, B. & Brula, A. Q. Intranasal esketamine: from origins to future implications in treatment-resistant depression. J. Psychiatr. Res. 137, 29\u201335 (2021).","journal-title":"J. Psychiatr. Res"},{"key":"226_CR13","unstructured":"Spravato product monograph. http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/SPRAVATO-pi.pdf."},{"key":"226_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","volume":"55","author":"MA Peltoniemi","year":"2016","unstructured":"Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T. & Saari, T. I. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin. Pharmacokinet. 55, 1059\u20131077 (2016).","journal-title":"Clin. Pharmacokinet."},{"key":"226_CR15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","volume":"278","author":"A Bahji","year":"2021","unstructured":"Bahji, A., Vazquez, G. H. & Zarate, C. A. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J. Affect Disord. 278, 542\u2013555 (2021).","journal-title":"J. Affect Disord."},{"key":"226_CR16","doi-asserted-by":"publisher","first-page":"1209419","DOI":"10.3389\/fpsyt.2024.1209419","volume":"15","author":"P Wolfson","year":"2024","unstructured":"Wolfson, P. & Vaid, G. Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective\u2014a new and evolving approach. Front. Psychiatry 15, 1209419 (2024).","journal-title":"Front. Psychiatry"},{"key":"226_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20190-4","volume":"11","author":"ED Ballard","year":"2020","unstructured":"Ballard, E. D. & Zarate, C. A. The role of dissociation in ketamine\u2019s antidepressant effects. Nat. Commun. 11, 6431 (2020).","journal-title":"Nat. Commun."},{"key":"226_CR18","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2174\/1570159X22666231027111147","volume":"22","author":"TG Zaretsky","year":"2024","unstructured":"Zaretsky, T. G. et al. The psychedelic future of post-traumatic stress disorder treatment. Curr. Neuropharmacol. 22, 636\u2013735 (2024).","journal-title":"Curr. Neuropharmacol."},{"key":"226_CR19","doi-asserted-by":"publisher","first-page":"917199","DOI":"10.3389\/fpsyt.2022.917199","volume":"13","author":"K Ko","year":"2022","unstructured":"Ko, K., Knight, G., Rucker, J. J. & Cleare, A. J. Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Front. Psychiatry 13, 917199 (2022).","journal-title":"Front. Psychiatry"},{"key":"226_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman, L., Nutt, D. J. & Carhart-Harris, R. L. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharm. 8, 974 (2017).","journal-title":"Front Pharm."},{"key":"226_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000517074","volume":"90","author":"ST Wilkinson","year":"2021","unstructured":"Wilkinson, S. T. et al. Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial. Psychother. Psychosom. 90, 318\u2013327 (2021).","journal-title":"Psychother. Psychosom."},{"key":"226_CR22","doi-asserted-by":"publisher","unstructured":"Swainson, J., Brietzke, E., Khullar, A., McIntyre, R. S. & Soares, C. N. Ketamine, psychedelics, and psychotherapy: reframing, redefining, renaming treatment models. Can. J. Psychiatry https:\/\/doi.org\/10.1177\/07067437251389090 (2025).","DOI":"10.1177\/07067437251389090"},{"key":"226_CR23","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/JPR.S360733","volume":"15","author":"SJ Drozdz","year":"2022","unstructured":"Drozdz, S. J. et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J. Pain. Res. 15, 1691\u20131706 (2022).","journal-title":"J. Pain. Res."},{"key":"226_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s40501-025-00346-z","volume":"12","author":"AM Gomes","year":"2025","unstructured":"Gomes, A. M. & Novais, F. Ketamine-assisted psychotherapy for treatment-resistant depression: a systematic review. Curr. Treat. Options Psychiatry 12, 14 (2025).","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"226_CR25","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.53","volume":"9","author":"BM Kew","year":"2023","unstructured":"Kew, B. M. et al. Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review. BJPsych Open 9, e79 (2023).","journal-title":"BJPsych Open"},{"key":"226_CR26","doi-asserted-by":"publisher","unstructured":"Simpson, R. J. & Juruena, M. F. Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: a systematic review. Psychopharmacology https:\/\/doi.org\/10.1007\/s00213-026-07003-0 (2026).","DOI":"10.1007\/s00213-026-07003-0"},{"key":"226_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2026.102706","volume":"124","author":"JKE Veraart","year":"2026","unstructured":"Veraart, J. K. E. et al. Ketamine-assisted psychotherapies for mental disorders: a historical overview and systematic review. Clin. Psychol. Rev. 124, 102706 (2026).","journal-title":"Clin. Psychol. Rev."},{"key":"226_CR28","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters, M. D. J. et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid. Synth. 18, 2119\u20132126 (2020).","journal-title":"JBI Evid. Synth."},{"key":"226_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco, A. C. et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann. Intern Med. 169, 467\u2013473 (2018).","journal-title":"Ann. Intern Med"},{"key":"226_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/da.22253","volume":"31","author":"RB Price","year":"2014","unstructured":"Price, R. B. et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 31, 335\u2013343 (2014).","journal-title":"Depress Anxiety"},{"key":"226_CR31","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s41386-023-01606-3","volume":"48","author":"O Duek","year":"2023","unstructured":"Duek, O. et al. Long term structural and functional neural changes following a single infusion of Ketamine in PTSD. Neuropsychopharmacology 48, 1648\u20131658 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"226_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000457960","volume":"86","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson, S. T. et al. Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother. Psychosom. 86, 162\u2013167 (2017).","journal-title":"Psychother. Psychosom."},{"key":"226_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/bs14080717","volume":"14","author":"J Rohde","year":"2024","unstructured":"Rohde, J. et al. Combined effects of nasal ketamine and trauma-focused psychotherapy in treatment-resistant post-traumatic stress disorder: a pilot case series. Behav. Sci. 14, 717 (2024).","journal-title":"Behav. Sci."},{"key":"226_CR34","first-page":"100613","volume":"14","author":"JL Phillips","year":"2023","unstructured":"Phillips, J. L., Blier, P. & Talbot, J. Sustaining the benefits of intravenous ketamine with behavioural activation therapy for depression: a case series. J. Affect. Disord. Rep. 14, 100613 (2023).","journal-title":"J. Affect. Disord. Rep."},{"key":"226_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1017\/S1478951522001304","volume":"21","author":"FE Forcen","year":"2023","unstructured":"Forcen, F. E., Marengo, L. & Behn, M. Ketamine-assisted meaning-centered psychotherapy for a patient with severe suicidal behavior. Palliat. Support. Care 21, 362\u2013364 (2023).","journal-title":"Palliat. Support. Care"},{"key":"226_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1127863","volume":"4","author":"D Batievsky","year":"2023","unstructured":"Batievsky, D. et al. Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches. Front. Pain. Res. 4, 1127863 (2023).","journal-title":"Front. Pain. Res."},{"key":"226_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","volume":"51","author":"J Dore","year":"2019","unstructured":"Dore, J. et al. Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J. Psychoact. Drugs 51, 189\u2013198 (2019).","journal-title":"J. Psychoact. Drugs"},{"key":"226_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1556\/2054.2021.00179","volume":"5","author":"AK Davis","year":"2021","unstructured":"Davis, A. K., Mangini, P. & Xin, Y. Ketamine assisted psychotherapy for trauma exposed patients in an outpatiet setting: a clinical chart review. J. Psychedelic Stud. 5, 94\u2013102 (2021).","journal-title":"J. Psychedelic Stud."},{"key":"226_CR39","unstructured":"Montjoy, J. F. Ketamine-assisted psychotherapy: Clinical outcomes and self-transcendence in depression and post-traumatic stress disorder. Dissertation Abstracts International: Section B: The Sciences and Engineering 84, No-Specified (2023)."},{"key":"226_CR40","unstructured":"Oswin, S. L. Differences in PHQ-9 depression severity between adults receiving ketamine or ketamine-assisted psychotherapy. Dissertation Abstracts International: Section B: The Sciences and Engineering 84, No-Specified (2023)."},{"key":"226_CR41","unstructured":"Willen, S. S. M. A program evaluation of ketamine assisted psychotherapy for treatment-resistant depression. Dissertation Abstracts International: Section B: The Sciences and Engineering 85, No-Specified (2024)."},{"key":"226_CR42","unstructured":"Luedeke, T. Impacts to Anxiety, Depression, and Psycho-Spiritual Metrics after Ketamine-Assisted Psychotherapy in Palliative Care Patients at the AIMS Institute [Doctor of Nursing Practice Project]. vol. Doctor of Nursing Practice (Seattle University, (2024)."},{"key":"226_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/02791072.2023.2186285","volume":"56","author":"R Robison","year":"2024","unstructured":"Robison, R. et al. Ketamine-assisted group psychotherapy for frontline healthcare workers with COVID-19-related burnout and PTSD: a case series of effectiveness\/safety for 10 participants. J. Psychoact. Drugs 56, 23\u201332 (2024).","journal-title":"J. Psychoact. Drugs"},{"key":"226_CR44","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.3390\/ijms26146673","volume":"26","author":"S Sakopoulos","year":"2025","unstructured":"Sakopoulos, S. & Todman, M. The effects of psychotherapy on single and repeated ketamine infusion(s) therapy for treatment-resistant depression: the convergence of molecular and psychological treatment. Int. J. Mol. Sci. 26, 6673 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"226_CR45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.genhosppsych.2026.02.001","volume":"99","author":"R Cohen","year":"2026","unstructured":"Cohen, R. et al. Ketamine combined with psychotherapy for treatment-resistant depression: real-world outcomes and the role of subjective experience. Gen. Hosp. Psychiatry 99, 179\u2013190 (2026).","journal-title":"Gen. Hosp. Psychiatry"},{"key":"226_CR46","doi-asserted-by":"publisher","first-page":"S183EP","DOI":"10.1016\/j.biopsych.2025.02.452","volume":"97","author":"R Kosted","year":"2025","unstructured":"Kosted, R., Waddell, A., Adolph, K. & Fonzo, G. 215. Association of adverse childhood experiences with depression symptom reduction following ketamine infusions: insights from a large, naturalistic sample. Biol. Psychiatry 97, S183EP\u2013S18184 (2025).","journal-title":"Biol. Psychiatry"},{"key":"226_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.71164","volume":"16","author":"FA Silva","year":"2026","unstructured":"Silva, F. A. et al. Ketamine combined with psychotherapy as a treatment for resistant depression in a public European hospital. Brain Behav. 16, e71164 (2026).","journal-title":"Brain Behav."},{"key":"226_CR48","doi-asserted-by":"publisher","unstructured":"Flynn, L., Rondeau, M., Krsak, M. & Shannon, S. Ketamine-assisted group therapy for work-related stress in first responders and frontline health care workers. Psychedelic Med. https:\/\/doi.org\/10.1089\/psymed.2024.0050 (2025).","DOI":"10.1089\/psymed.2024.0050"},{"key":"226_CR49","doi-asserted-by":"publisher","first-page":"1160442","DOI":"10.3389\/fpsyt.2023.1160442","volume":"14","author":"E Whinkin","year":"2023","unstructured":"Whinkin, E., Eparwa, T. R. J., Julseth, M. C., Schneider, A. & Aggarwal, S. K. Reductions in anxiety and depression symptoms in a subset of outpatients with problematic substance use who received ketamine-assisted psychotherapy: a two-year retrospective chart review. Front Psychiatry 14, 1160442 (2023).","journal-title":"Front Psychiatry"},{"key":"226_CR50","unstructured":"Alapizco, I. Evaluating Group Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression and Trauma-Related Symptoms. (2024)."},{"key":"226_CR51","doi-asserted-by":"publisher","first-page":"1020214","DOI":"10.3389\/fpsyt.2022.1020214","volume":"13","author":"J Willms","year":"2022","unstructured":"Willms, J. et al. Case report: medical student types journals during ketamine infusions for suicidal ideation, treatment-resistant depression, post-traumatic stress disorder, and generalized anxiety disorder. Front. Psychiatry 13, 1020214 (2022).","journal-title":"Front. Psychiatry"},{"key":"226_CR52","doi-asserted-by":"publisher","first-page":"1197409","DOI":"10.3389\/fnins.2023.1197409","volume":"17","author":"E Argento","year":"2023","unstructured":"Argento, E. et al. Case report: improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy. Front Neurosci. 17, 1197409 (2023).","journal-title":"Front Neurosci."},{"key":"226_CR53","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/JCP.0000000000001726","volume":"43","author":"J Zambrano","year":"2023","unstructured":"Zambrano, J. & Forcen, F. E. Challenges with short-term use of intravenous racemic ketamine with psychotherapy for a hospitalized patient with severe posttraumatic stress disorder and depression. J. Clin. Psychopharmacol. 43, 462\u2013464 (2023).","journal-title":"J. Clin. Psychopharmacol."},{"key":"226_CR54","doi-asserted-by":"publisher","unstructured":"Hicks, M. R., Zwickey, H. & Bradley, R. Ketamine-assisted psychotherapy for antisocial personality disorder: a case report. J. Psychoact. Drugs 1\u20137. https:\/\/doi.org\/10.1080\/02791072.2025.2449911 (2025).","DOI":"10.1080\/02791072.2025.2449911"},{"key":"226_CR55","doi-asserted-by":"publisher","unstructured":"Cohen, J. et al. Ketamine-assisted psychotherapy for generalized anxiety disorder: a comprehensive case report with integrated neurophysiological imaging using magnetoencephalography. medRxiv https:\/\/doi.org\/10.1101\/2025.02.25.25322463 (2025).","DOI":"10.1101\/2025.02.25.25322463"},{"key":"226_CR56","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1521\/pedi.2025.39.2.170","volume":"39","author":"A Yeung","year":"2025","unstructured":"Yeung, A., Alpert, M. & Mischoulon, D. Ketamine-assisted psychotherapy for treatment of co-occurring borderline personality disorder and depression: a case study. J. Personal. Disord. 39, 170\u2013184 (2025).","journal-title":"J. Personal. Disord."},{"key":"226_CR57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.24869\/psyd.2025.383","volume":"37","author":"R Rijal","year":"2025","unstructured":"Rijal, R., Pokhrel, P., Shrestha, P. & Adhikari, D. Revisiting ketamine abreaction: a case report in depressive and dissociative symptomatology. Psychiatr. Danub 37, 383\u2013385 (2025).","journal-title":"Psychiatr. Danub"},{"key":"226_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s40337-025-01313-y","volume":"13","author":"CL Dahlgren","year":"2025","unstructured":"Dahlgren, C. L., Tverrli, E. & Stewart, L. H. Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa. J. Eat. Disord. 13, 107 (2025).","journal-title":"J. Eat. Disord."},{"key":"226_CR59","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1192\/bjp.2025.102","volume":"228","author":"KT Greenway","year":"2026","unstructured":"Greenway, K. T. et al. The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression. Br. J. Psychiatry 228, 437\u2013445 (2026).","journal-title":"Br. J. Psychiatry"},{"key":"226_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1727487","volume":"16","author":"JM Sevelius","year":"2025","unstructured":"Sevelius, J. M. et al. Ketamine-assisted group psychotherapy integrating cognitive processing therapy to address identity-based trauma: a pilot study. Front. Psychiatry 16, 1727487 (2025).","journal-title":"Front. Psychiatry"},{"key":"226_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s40337-022-00588-9","volume":"10","author":"R Robison","year":"2022","unstructured":"Robison, R. et al. A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders. J. Eat. Disord. 10, 65 (2022).","journal-title":"J. Eat. Disord."},{"key":"226_CR62","doi-asserted-by":"publisher","first-page":"803279","DOI":"10.3389\/fpsyt.2021.803279","volume":"12","author":"S Dames","year":"2021","unstructured":"Dames, S., Kryskow, P. & Watler, C. A cohort-based case report: the impact of ketamine-assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression. Front. Psychiatry 12, 803279 (2021).","journal-title":"Front. Psychiatry"},{"key":"226_CR63","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/02791072.2023.2253798","volume":"56","author":"VWL Tsang","year":"2024","unstructured":"Tsang, V. W. L., Ragazan, D. C., Kryskow, P., Walsh, Z. & Dames, S. A pilot study comparing a community of practice program with and without concurrent ketamine-assisted therapy. J. Psychoact. drugs 56, 627\u2013636 (2024).","journal-title":"J. Psychoact. drugs"},{"key":"226_CR64","doi-asserted-by":"publisher","unstructured":"Ryan, W. C. & Heifets, B. D. Maintenance intramuscular ketamine-assisted psychotherapy, a retrospective chart review of efficacy, adverse events, and dropouts from a community practice. J. Psychoact. Drugs 1\u201315. https:\/\/doi.org\/10.1080\/02791072.2024.2421895 (2024).","DOI":"10.1080\/02791072.2024.2421895"},{"key":"226_CR65","doi-asserted-by":"crossref","unstructured":"Stefanuk, I. et al. A retrospective report of a ketamine augmented, transdiagnostic psychiatric outpatient psychotherapy program. J. Mil. Veteran Fam. Health 12, 65\u201375 (2026).","DOI":"10.3138\/jmvfh-2025-0009"},{"key":"226_CR66","doi-asserted-by":"publisher","first-page":"1322679","DOI":"10.3389\/fpsyt.2024.1322679","volume":"15","author":"CP Harris","year":"2024","unstructured":"Harris, C. P., Jones, B., Walker, K. & Berry, M. S. Case report: adult with bipolar disorder and autism treated with ketamine assisted psychotherapy. Front. Psychiatry 15, 1322679 (2024).","journal-title":"Front. Psychiatry"},{"key":"226_CR67","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/psymed.2023.0021","volume":"2","author":"R Yermus","year":"2024","unstructured":"Yermus, R. et al. Ketamine-assisted psychotherapy provides lasting and effective results in the treatment of depression, anxiety, and post-traumatic stress disorder at 3 and 6 months: findings from a large retrospective effectiveness study. Psychedelic Med. 2, 87\u201395 (2024).","journal-title":"Psychedelic Med."},{"key":"226_CR68","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jad.2025.04.041","volume":"381","author":"TM Moore","year":"2025","unstructured":"Moore, T. M. et al. Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. J. Affect. Disord. 381, 233\u2013241 (2025).","journal-title":"J. Affect. Disord."},{"key":"226_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s40337-024-01039-3","volume":"12","author":"A Timek","year":"2024","unstructured":"Timek, A., Daniels-Brady, C. & Ferrando, S. Improvement in depressive symptoms in a patient with severe and enduring anorexia nervosa and comorbid major depressive disorder using psychotherapy-assisted IV ketamine: a case report. J. Eat. Disord. 12, 79 (2024).","journal-title":"J. Eat. Disord."},{"key":"226_CR70","doi-asserted-by":"publisher","first-page":"100572","DOI":"10.1016\/j.ejtd.2025.100572","volume":"9","author":"S Almog","year":"2025","unstructured":"Almog, S., Garcia-Romeu, A., Walker, K. A., Weiner, M. & Berry, M. S. Self-reported improvements in comorbid post-traumatic stress disorder symptoms, depression, anxiety, and sleep among real-world patients receiving medical ketamine: exploring the role of adjunct therapies. Eur. J. Trauma Dissociation 9, 100572 (2025).","journal-title":"Eur. J. Trauma Dissociation"},{"key":"226_CR71","unstructured":"Tustison, J. Mindfulness Meditation as an Adjunct to Esketamine Treatment for Major Depressive Disorder (UCLA, 2025)."},{"key":"226_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15883","volume":"9","author":"JKE Veraart","year":"2023","unstructured":"Veraart, J. K. E. et al. Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder. Heliyon 9, e15883 (2023).","journal-title":"Heliyon"},{"key":"226_CR73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/02698811241267837","volume":"39","author":"L Gutierrez-Rojas","year":"2025","unstructured":"Gutierrez-Rojas, L. et al. Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment. J. Psychopharmacol. 39, 38\u201348 (2025).","journal-title":"J. Psychopharmacol."},{"key":"226_CR74","doi-asserted-by":"crossref","unstructured":"Roullet, P., Pons, L.-L., Delmas, P., Weber, C. & de Prigny, P. R. Esketamine facilitate psychotherapies for post-traumatic stress disorder: a retrospective case series of six patients. Eur. J. Trauma. Dissociation 9, 100490 (2025).","DOI":"10.1016\/j.ejtd.2024.100490"},{"key":"226_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1291077","volume":"14","author":"A Kaltenboeck","year":"2023","unstructured":"Kaltenboeck, A. et al. Clinical case report: considerable improvement of severe and difficult-to-treat obsessive-compulsive disorder with comorbid depression under treatment with esketamine and concomitant psychotherapy. Front. Psychiatry 14, 1291077 (2023).","journal-title":"Front. Psychiatry"},{"key":"226_CR76","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1176\/appi.ajp.20220216","volume":"179","author":"RB Price","year":"2022","unstructured":"Price, R. B. et al. A novel, brief, fully automated intervention to extend the antidepressant effect of a single ketamine infusion: a randomized clinical trial. Am. J. Psychiatry 179, 959\u2013968 (2022).","journal-title":"Am. J. Psychiatry"},{"key":"226_CR77","unstructured":"Mithoefer, A. et al. A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder, Version 7. (2015)."},{"key":"226_CR78","doi-asserted-by":"publisher","first-page":"121350","DOI":"10.1016\/j.jad.2026.121350","volume":"402","author":"R Kosted","year":"2026","unstructured":"Kosted, R., Waddell, A., Adolph, K. & Fonzo, G. A. Age-related moderation of adjunctive psychotherapy and early life stress effects on depression symptom reductions following ketamine treatment: Initial insights from a large, naturalistic sample. J. Affect. Disord. 402, 121350 (2026).","journal-title":"J. Affect. Disord."},{"key":"226_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115585","volume":"330","author":"BM Kitay","year":"2023","unstructured":"Kitay, B. M. et al. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: the CBT-ENDURE randomized clinical trial study protocol. Psychiatry Res. 330, 115585 (2023).","journal-title":"Psychiatry Res"},{"key":"226_CR80","doi-asserted-by":"publisher","first-page":"1283733","DOI":"10.3389\/fpsyt.2023.1283733","volume":"14","author":"C Chrenek","year":"2023","unstructured":"Chrenek, C. et al. Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada. Front Psychiatry 14, 1283733 (2023).","journal-title":"Front Psychiatry"},{"key":"226_CR81","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cpt.3391","volume":"116","author":"SM Raja","year":"2024","unstructured":"Raja, S. M. et al. A phase 1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-hydroxynorketamine in healthy volunteers. Clin. Pharm. Ther. 116, 1314\u20131324 (2024).","journal-title":"Clin. Pharm. Ther."},{"key":"226_CR82","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4103\/ijp.ijp_907_24","volume":"57","author":"J Ashwin","year":"2025","unstructured":"Ashwin, J., Shahi, M. K., Singh, A. & Kumar, S. T. Efficacy and safety of dextromethorphan\u2013bupropion combination (AXS-05) in the treatment of depression: a systematic review and network meta-analysis. Indian J. Pharm. 57, 262\u2013268 (2025).","journal-title":"Indian J. Pharm."},{"key":"226_CR83","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40263-024-01114-y","volume":"38","author":"RS McIntyre","year":"2024","unstructured":"McIntyre, R. S. & Jain, R. Glutamatergic modulators for major depression from theory to clinical use. CNS Drugs 38, 869\u2013890 (2024).","journal-title":"CNS Drugs"},{"key":"226_CR84","doi-asserted-by":"crossref","unstructured":"Chubbs, B. et al. A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: a preliminary evaluation of real world addictive potential. Front. Psychiatry 13, 1016439 (2022).","DOI":"10.3389\/fpsyt.2022.1016439"},{"key":"226_CR85","first-page":"149","volume":"5","author":"WN Pahnke","year":"1969","unstructured":"Pahnke, W. N. Psychedelic drugs and mystical experience. Int. Psychiatry Clin. 5, 149\u2013162 (1969).","journal-title":"Int. Psychiatry Clin."},{"key":"226_CR86","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fnhum.2016.00269","volume":"10","author":"MM Nour","year":"2016","unstructured":"Nour, M. M., Evans, L., Nutt, D. & Carhart-Harris, R. L. Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). Front. Hum. Neurosci. 10, 269 (2016).","journal-title":"Front. Hum. Neurosci."},{"key":"226_CR87","unstructured":"Hanon, N. et al. Outpatient Use of Ketamine for Mental Health Conditions: Practice Standards and Recommendations Ketamine Assisted Therapy Association of Canada, Version 4. (2023)."},{"key":"226_CR88","unstructured":"Wolfson, P. & Braunstein, M. Ketamine States: A Journey Through the Mind. https:\/\/maps.org\/news\/bulletin\/ketamine-states-krf-guidebook\/."},{"key":"226_CR89","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","volume":"74","author":"G Sanacora","year":"2017","unstructured":"Sanacora, G. et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74, 399\u2013405 (2017).","journal-title":"JAMA Psychiatry"},{"key":"226_CR90","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/00048674251333577","volume":"59","author":"S Hussain","year":"2025","unstructured":"Hussain, S. et al. Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice. Aust. N. Z. J. Psychiatry 59, 576\u2013587 (2025).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"226_CR91","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jad.2020.01.120","volume":"266","author":"B Short","year":"2020","unstructured":"Short, B. et al. Development of the Ketamine Side Effect Tool (KSET). J. Affect Disord. 266, 615\u2013620 (2020).","journal-title":"J. Affect Disord."},{"key":"226_CR92","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W. & Griffiths, R. R. The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. J. Psychopharmacol. 30, 1279\u20131295 (2016).","journal-title":"J. Psychopharmacol."}],"container-title":["npj Mental Health Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44184-026-00226-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44184-026-00226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44184-026-00226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:03:27Z","timestamp":1787227407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44184-026-00226-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["226"],"URL":"https:\/\/doi.org\/10.1038\/s44184-026-00226-1","relation":{},"ISSN":["2731-4251"],"issn-type":[{"value":"2731-4251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S. has received honoraria for speaking and advising\/consulting from AbbVie, Bausch Health, Eisai, Idorsia, Janssen, Lundbeck, Novo Nordisk, Otsuka, and the College of Physicians and Surgeons of Alberta and is supported by the Alberta Academic Medicine and Health Services Program (AMHSP). P.G., S.P., C.B., and G.G. declare no competing interests. Y.Z., O.W., and L.B. are supported by the Alberta Academic Medicine and Health Services Program (AMHSP) and have no competing interests. A.K. has received honoraria for speaking and advising\/consulting from AbbVie, Bausch Health, Eisai, Elvium, Idorsia, Jazz, Lundbeck, and Otsuka. R.S.M. has received research grant support from CIHR\/GACD\/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker\/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, AbbVie, and Atai Life Sciences. E.B. has received honoraria from Biocase for education activities in PAP. C.N.S. has received honoraria for advising\/consulting from Otsuka, Diamond Therapeutics, Eisai, Idorsia, Bayer, Astellas, AbCellera and received research grants from Clairvoyant Therapeutics, Eisai, Diamond Therapeutics and the Ontario Brain Institute. Author C.N.S. is a co-Guest Editor for this Nature Mental Health special collection on Psychedelics, but was not involved in the journal\u2019s review of, or decisions related to, this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"43"}}